The suite includes a designated area for the small-scale development and manufacturing of solid dosage forms for customers’ early clinical study needs.
The 2,500sqft suite is designed to give rapid response, and the facility is good manufacturing practice-compliant for manufacturing products for Phase I and II clinical studies, the company said. By providing clinical trial materials for first time in human (Phase I) studies, the suite will contribute to its Quick To Clinic offering, added Patheon. The new facility will also add early-phase pharmaceutical development and manufacturing capacity, with a manufacturing scale of 1kg to 10kg.
The suite has multiple labs with the capability for small-scale dosage form development, as well as the manufacture of powder-in-bottle, tablets (immediate and modified release), capsules, oral liquids and nasal sprays.
Colin Minchom, Patheon’s vice president of pharmaceutical development services for Canada, said: “We’re very excited about the rapid response capabilities of the new Whitby suite. This new facility will significantly strengthen Patheon’s competitiveness in the pharmaceutical and biotechnology early development arena.”